Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194


Stem cell transplantation for the management of primary systemic amyloidosis.

Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, Litzow MR.

Am J Med. 2002 Nov;113(7):549-55.


Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.


Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M.

Blood. 1996 Oct 1;88(7):2801-6.


Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).

Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA, Litzow MR.

Bone Marrow Transplant. 2000 Nov;26(9):963-9.


An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.


Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.

Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.

Haematologica. 2006 Dec;91(12):1635-43.


Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.

Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.

Am J Kidney Dis. 2005 Aug;46(2):270-7. Review.


High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.


Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.

Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.

Wien Klin Wochenschr. 2006 Feb;118(1-2):49-53.


Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.

Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M; Immunopathology Group of the Italian Society of Nephrology.

Nephrol Dial Transplant. 2008 Mar;23(3):941-51. Epub 2007 Oct 19.


Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study.

Blum W, Khoury H, Lin HS, Vij R, Goodnough LT, Devine S, Dipersio J, Adkins D.

Biol Blood Marrow Transplant. 2003 Jun;9(6):397-404.


Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.

Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, Naka Y, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D.

Transplantation. 2007 Mar 15;83(5):539-45.


Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA.

J Heart Lung Transplant. 2008 Aug;27(8):823-9. doi: 10.1016/j.healun.2008.05.016. Epub 2008 Jul 3.


Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.

Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.

Ann Hematol. 2009 Jul;88(7):681-5. doi: 10.1007/s00277-008-0652-z. Epub 2008 Dec 6.


Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M.

Ann Intern Med. 2001 May 1;134(9 Pt 1):746-53.


Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.

Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.

Ann Hematol. 2010 Jun;89(6):579-84. doi: 10.1007/s00277-009-0874-8. Epub 2009 Dec 10.


The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.

Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI; British Society of Blood and Marrow Transplantation.

Br J Haematol. 2006 Aug;134(4):385-90. Epub 2006 Jul 5.


Amyloidosis: review of 236 cases.

Kyle RA, Bayrd ED.

Medicine (Baltimore). 1975 Jul;54(4):271-99.


Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.

Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F.

Arch Cardiovasc Dis. 2008 Sep;101(9):523-32. doi: 10.1016/j.acvd.2008.06.018. Epub 2008 Nov 17.

Supplemental Content

Support Center